Enhancer of zeste homolog 2 (EZH2), which is the catalytic subunit of polycomb repressive complex 2, enhances tumorigenesis and is commonly overexpressed in several types of cancer.1 Moreover, EZH2 has been reported to have an essential role in self-renewal of cancer stem cells,2 indicating that EZH2-targeting drugs can act as potent anticancer agents. This evidence concerns the gene EZH2 and cancer.